Subscribe to RSS
Outcomes of Adult Ewing Sarcoma Treated with Multimodality Therapy: A Single-Institute Experience
Introduction Ewing sarcoma (ES) is more common in children and relatively rare in adults. Adult ES has poor prognosis than children. Treatment approaches for adults have been extrapolated from pediatric experience. Data on adult ES are very few because of its rarity in adults. The present study was done to analyze the clinical profile and outcome of adult ES.
Aims The aim was to study the clinical and pathological treatment and outcomes in adult ES.
Subjects and Methods Between 2010 and 2017, a total of 73 ES patients with age more than 18 years were retrospectively analyzed. Survival analysis was done by plotting Kaplan–Meier curves.
Results A total of 73 patients were diagnosed with ES during 2010 to 2017. Among them, 43 (58.9%) had localized disease with a median age of 24.5 years. Males were 44 (60.3%) and females were 29 (39.7). Pain (75.3%) was the most common symptom at presentation. Nine patients had incomplete details and were excluded from the analysis. Among 21 (28.8%) patients, the lung (61.9%) was the most common site of metastasis followed by the bone, bone marrow, and brain. The median number of chemotherapy cycles in the localized disease was 14 (range 1–17), and in metastatic disease, it was 4 (range 1–7). Univariate analysis was done with respect to age (< 25 vs. ≥25), gender, elevated or normal serum lactate dehydrogenase level, tumor size (< 8 cm versus ≥8 cm), site (axial versus extremity), and neoadjuvant chemotherapy (NACT) given or not. NACT had a significant impact on overall survival (OS) and the rest had no effect. At a median follow-up of 40 months, the 3-year OS in localized disease was 87.4%. In metastatic disease, the median OS was 13 months with 3-year OS of 26%.
Conclusions Outcomes with multimodality therapy in adult ES patients with localized disease are comparable to that of a pediatric cohort. However, metastatic disease has poor survival.
04 July 2021 (online)
© 2021. MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
Thieme Medical and Scientific Publishers Private Ltd
A-12, Second Floor, Sector -2, NOIDA -201301, India
- 1 Glass AG, Fraumeni Jr JF. Epidemiology of bone cancer in children. J Natl Cancer Inst 1970; 44 (01) 187-199
- 2 Nesbit Jr ME, Gehan EA, Burgert r EO. et al. Multimodal therapy for the management of primary, nonmetastatic Ewing’s sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin Oncol 1990; 8 (10) 1664-1674
- 3 Burgert EO Jr, Nesbit ME, Garnsey LA. et al. Multimodal therapy for the management of nonpelvic, localized Ewing’s sarcoma of bone: intergroup study IESS-II. J Clin Oncol 1990; 8 (09) 1514-1524
- 4 Grier HE, Krailo MD, Tarbell NJ. et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing’s sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003; 348 (08) 694-701
- 5 Granowetter L, Womer R, Devidas M. et al. Dose-intensified compared with standard chemotherapy for nonmetastatic Ewing sarcoma family of tumors: a Children’s Oncology Group Study. J Clin Oncol 2009; 27 (15) 2536-2541
- 6 Womer RB, West DC, Krailo MD. et al. Randomized controlled trial of interval-compressed chemotherapy for the treatment of localized Ewing sarcoma: a report from the Children’s Oncology Group. J Clin Oncol 2012; 30 (33) 4148-4154
- 7 Lin PP, Jaffe N, Herzog CE. et al. Chemotherapy response is an important predictor of local recurrence in Ewing sarcoma. Cancer 2007; 109 (03) 603-611
- 8 Gaspar N, Hawkins DS, Dirksen U. et al. Ewing sarcoma: current management and future approaches through collaboration. J Clin Oncol 2015; 33 (27) 3036-3046
- 9 Verma V, Denniston KA, Lin CJ, Lin C. A comparison of pediatric versus adult patients with the Ewing sarcoma family of tumors. Front Oncol 2017; 7: 82
- 10 Ahmed SK, Robinson SI, Okuno SH, Rose PS, Laack NN. Adult ewing sarcoma: survival and local control outcomes in 102 patients with localized disease. Sarcoma 2013; 2013: 681425
- 11 Pretz JL, Barysauskas CM, George S. et al. Localized adult Ewing sarcoma: favorable outcomes with alternating vincristine, doxorubicin, cyclophosphamide, and ifosfamide, etoposide (VDC/IE)-based multimodality therapy. Oncologist 2017; 22 (10) 1265-1270
- 12 Verrill MW, Judson IR, Wiltshaw E, Thomas JM, Harmer CL, Fisher C. The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing’s family tumours. Ann Oncol 1997; 8 (11) 1099-1105
- 13 Nasaka S, Gundeti S, Ganta RR, Arigela RS, Linga VG, Maddali LS. Impact of treatment protocol on outcome of localized Ewing’s sarcoma. South Asian J Cancer 2016; 5 (04) 194-195